logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2020 – Combining immune and targeted therapy in advanced melanoma with BRAFV600 mutations

The IMspire150 trial evaluated a new combination strategy in treatment-naive patients by adding the immune checkpoint inhibitor atezolizumab to the targeted therapy with cobimetinib and vemurafenib.